about
Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectinAtomic Basis for the Species-specific Inhibition of V Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of V 3 Ectodomain-17E6 Fab ComplexDecreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma.New insights into the structural basis of integrin activation.Integrins αvβ3 and αvβ5 as prognostic, diagnostic, and therapeutic targets in gastric cancerStructure and mechanics of integrin-based cell adhesion.Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcomeCirculating and imaging markers for angiogenesis.Invasion patterns in brain metastases of solid cancersIntegrins as therapeutic targets.αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities.Integrin control of the transforming growth factor-β pathway in glioblastoma.Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro.Integrins as Therapeutic Targets: Successes and Cancers.Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression.Divalent cations and the relationship between alphaA and betaA domains in integrins.Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation.alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.Improving implant materials by coating with nonpeptidic, highly specific integrin ligands.Titanium implant materials with improved biocompatibility through coating with phosphonate-anchored cyclic RGD peptides.Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and alpha(v)beta3 are critical.Piltdown wasn't cricket but does the hobbit ring true?Distinctive role of integrin-mediated adhesion in TNF-induced PKB/Akt and NF-kappaB activation and endothelial cell survival.Cell-cell interaction and polarity of epithelial cells: specific perturbation using a monoclonal antibody.The 3rd Antibody Validation meeting: Bath UK 20-21 September 2018Integrins in cell migrationPharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitroMonitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapyThe αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma modelThe path to VICTORy - a beginner's guide to success using commercial research antibodiesNeovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy
P50
Q24292863-DFB8F206-BE3E-4C7F-AEB3-141702A3E216Q27682746-F35FE8D3-B3A5-4308-9B6D-604D39478EAEQ33833912-AB9BC346-3556-439F-B2D3-312042B9313CQ34828108-8F0D06B8-E136-4090-828E-A127CEA16610Q35114650-9D9F2526-FBF3-4E78-9BB5-97320B412B94Q36065429-88B1F3AA-FD59-4AA2-B1CC-5D8D5F747B7FQ36744293-1BE5B16E-91B9-4420-B618-2D349E1F925AQ37046781-8FBDD2E3-4BD3-45B5-A9DB-B560AB658F16Q37299872-9963F3C7-27AB-4A4C-93A1-C634C0EFD2EAQ37312688-F1937260-3A5B-494D-B699-205F8BBAAE58Q38013361-69D3FF3F-8D39-4744-9E52-9C942B934069Q38242534-F4D957B3-FC27-4D8F-BD67-5A44975807F2Q38397937-9FAD9A6F-B36D-400D-B7EC-757EB330729BQ39200138-97EFF480-9713-4072-8697-6A5A9A9988EEQ40522209-6979A8EA-B58A-4BF1-BD92-6AE0E691EAD2Q41670949-4E07434A-BB02-42DE-BE37-92981B166344Q43501092-8EFC0887-5DA6-493D-90D4-0D1261C0B181Q44126740-23380AB5-68A3-4B15-AC9D-91E0779B2326Q44457063-355274C3-EB55-4113-AE47-129BD8721C55Q44739379-2A12DC0A-FA0D-49D8-8934-901A757E210BQ45184176-97441056-5EA0-4F8F-8AE6-85C3753FE067Q46737034-0EA85511-B59C-4842-A9CC-B3939A35CBA9Q46757487-DC913CAE-1FD3-4673-9020-90B22CAA33A3Q47184590-C22D4E48-405E-4DD7-8D2F-371188C60430Q52577777-2F5C22A8-E3B0-4969-BECB-7DA77F1CA73FQ55062706-48B134AA-69D8-4F5A-902D-1757036195C9Q60923774-15DBF16B-17B5-499B-AFEA-EB8097B3E779Q73012973-D294C256-AE47-4F12-888C-4E97381DD0B6Q79675607-5E6D3249-20F0-4053-B50E-A2A45DC75892Q81094664-808CACC1-A60A-4F7F-9398-9AED8B799D75Q85436603-42141AFD-5841-4B59-B3CE-B8429C308FE5Q88683594-D14A0564-67D8-441E-8967-6AD53AC294F6Q95804799-B7822082-17A0-435D-9F75-B460E725A2F6
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-3480-1346
@en
name
Simon L Goodman
@ast
Simon L Goodman
@en
Simon L Goodman
@nl
type
label
Simon L Goodman
@ast
Simon L Goodman
@en
Simon L Goodman
@nl
prefLabel
Simon L Goodman
@ast
Simon L Goodman
@en
Simon L Goodman
@nl
P106
P31
P496
0000-0002-3480-1346